Integrated Filing — IndAS



General information about company

Scrip Code 506235
NSE Symbol ALEMBICLTD
MSEI Symbol NOTLISTED
ISIN INE426A01027
Name of company Alembic Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 19-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 08-05-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 19-05-2026   16:30:00
End date and time of board meeting 19-05-2026   17:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 07-02-2025
Indicate Company website link for updated RPT policy of the Company https://alembiclimited.com/policy/Related-Party-Transaction-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,773.32 23,193.16
Other income 240.92 7,277.04
Total income 6,014.24 30,470.20
2 Expenses
(a) Cost of materials consumed 404.07 1,387.54
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (64.56) 255.12
(d) Employee benefit expense 1,174.32 3,744.49
(e) Finance costs 36.82 156.74
(f) Depreciation, depletion and amortisation expense 325.02 1,200.60
(f) Other Expenses
1 Cost of Construction 1,463.50 6,001.74
2 Other Expenses 841.29 3,034.96
Total other expenses 2,304.79 9,036.70
Total expenses 4,180.46 15,781.19
3 Total profit before exceptional items and tax 1,833.78 14,689.01
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,833.78 14,689.01
6 Tax expense
7 Current tax 550.27 2,200.00
8 Deferred tax 330.54 35.18
9 Total tax expenses 880.81 2,235.18
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 952.97 12,453.83
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 952.97 12,453.83
17 Other comprehensive income net of taxes (10,428.51) (9,464.55)
18 Total Comprehensive Income for the period (9,475.54) 2,989.28
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 5,135.64 5,135.64
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 62,563.67
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.37 4.85
Diluted earnings (loss) per share from continuing operations 0.37 4.85
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.37 4.85
Diluted earnings (loss) per share from continuing and discontinued operations 0.37 4.85
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The above results have been audited by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company. 2. The Board has recommended Dividend on equity shares at Rs 2.40 per share (face value Rs. 2/- each) i.e 120% for the year ended on 31st March, 2026 (Previous year Rs. 2.40 per share i.e 120%.) 3. The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year. 4. The figures for the quarter ended 31st March, 2026 and corresponding quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year and year to date figures upto third quarter of the respective financial years which were subject to limited review. 5. The Government of India has notified the implementation of four new Labour Codes effective 21st November, 2025, by consolidating and rationalizing 29 existing labour laws. The Company has provisionally estimated the financial implications thereof and has made additional provision under 'Employee Benefit Expense' for Rs. 143.72 lakh in the financial results for the quarter ended on 31st December, 2025. This will be reviewed and revised, if required once all applicable Rules are notified by the Government on all aspects of the Codes. 6. Figures rounded off to the nearest decimal.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 31-03-2026
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 16,995.22
Capital work-in-progress 150.21
Investment property 29,959.11
Goodwill 0.00
Other intangible assets 0.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 25,984.62
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets
1 Other non-current financial assets 496.51
Total of other non-current financial assets 496.51
Total non-current financial assets 26,481.13
Deferred tax assets (net) 0.00
Other non-current assets
1 Other non-current assets 3,500.00
Total of other non-current assets 3,500.00
Total non-current assets 77,085.67
2 Current assets
Inventories 5,224.11
Current financial asset
Current investments 8,905.00
Trade receivables, current 3,020.84
Cash and cash equivalents 109.90
Bank balance other than cash and cash equivalents 187.33
Loans, current 0.00
Other current financial assets
Total of other current financial assets 353.04
Total current financial assets 12,576.11
Current tax assets (net) 0.00
Other current assets
1 Other current assets 884.34
Total of other current assets 884.34
Total current assets 18,684.56
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 95,770.23
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 5,135.64
Other equity 77,010.00
Total equity attributable to owners of parent 82,145.64
Non controlling interest
Total equity 82,145.64
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 661.08
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities
1 Other non-current financial liabilities 1,020.58
Total of other non-current financial liabilities 1,020.58
Total non-current financial liabilities 1,681.66
Provisions, non-current 371.53
Deferred tax liabilities (net) 1,940.87
Deferred government grants, Non-current 0.00
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 3,994.06
Current liabilities
Current financial liabilities
Borrowings, current 402.77
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 677.24
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,618.91
Total Trade payable 2,296.15
Other current financial liabilities
1 Other current financial liabilities 800.44
Total of other current financial liabilities 800.44
Total current financial liabilities 3,499.36
Other current liabilities 2,837.88
1 Other current liabilities 2,837.88
Total of other current liabilities 2,837.88
Provisions, current 2,280.05
Current tax liabilities (Net) 1,013.24
Deferred government grants, Current
Total current liabilities 9,630.53
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 13,624.59
Total equity and liabilites 95,770.23
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-01-2026 01-04-2025
Date of end of reporting period 31-03-2026 31-03-2026
Whether results are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Active Pharmaceutical Ingredients Business 0.0098312 4,658.52
2 Real Estate Business 4,790.19 18,534.64
Total Segment Revenue 5,773.31 23,193.16
Less: Inter segment revenue 0.00 0.00
Revenue from operations 5,773.31 23,193.16
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Active Pharmaceutical Ingredients Business (117.08) 564.95
2 Real Estate Business 2,067.05 7,858.90
Total Profit before tax 1,949.97 8,423.85
i. Finance cost 36.82 156.74
ii. Other Unallocable Expenditure net off Unallocable income 79.36 (6,421.90)
Profit before tax 1,833.79 14,689.01
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Active Pharmaceutical Ingredients Business 18,081.25 18,081.25
2 Real Estate Business 50,165.22 50,165.22
Total Segment Asset 68,246.47 68,246.47
Un-allocable Assets 27,523.77 27,523.77
Net Segment Asset 95,770.24 95,770.24
4 Segment Liabilities
Segment Liabilities
1 Active Pharmaceutical Ingredients Business 3,480.44 3,480.44
2 Real Estate Business 7,190.04 7,190.04
Total Segment Liabilities 10,670.48 10,670.48
Un-allocable Liabilities 2,954.12 2,954.12
Net Segment Liabilities 13,624.60 13,624.60
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-01-2026 01-04-2025
B Date of end of reporting period 31-03-2026 31-03-2026
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Amount of items that will not be reclassified to profit and loss (11,668.03) (10,362.79)
Total Amount of items that will not be reclassified to profit and loss (11,668.03) (10,362.79)
2 Income tax relating to items that will not be reclassified to profit or loss (1,239.52) (898.24)
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (10,428.51) (9,464.55)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 31-03-2026
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 14,689.01
Adjustments for reconcile profit (loss)
Adjustments for finance costs 156.74
Adjustments for decrease (increase) in inventories 4,714.59
Adjustments for decrease (increase) in trade receivables, current (231.84)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 325.30
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 305.43
Adjustments for other financial assets, current (34.40)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (462.61)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (1,415.21)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 1,200.60
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 157.68
Adjustments for provisions, non-current 128.50
Adjustments for other financial liabilities, current 171.88
Adjustments for other financial liabilities, non-current 329.36
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 6,295.16
Adjustments for interest income 139.69
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 36.83
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (1,052.00)
Net cash flows from (used in) operations 13,637.01
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 1,897.15
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 11,739.86
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 13,029.30
Other cash payments to acquire equity or debt instruments of other entities 16,981.54
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 0.00
Purchase of property, plant and equipment 3,824.54
Proceeds from sales of investment property 0.00
Purchase of investment property 3,840.58
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 6,295.16
Interest received 139.69
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (21.46)
Net cash flows from (used in) investing activities (5,203.97)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 380.89
Payments of lease liabilities 0.00
Dividends paid 6,141.43
Interest paid 156.74
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (6,679.06)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (143.17)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents (143.17)
Cash and cash equivalents cash flow statement at beginning of period 253.04
Cash and cash equivalents cash flow statement at end of period 109.87





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 CNK & Associates LLP Yes 31-07-2027


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 ALEMBIC LIMITED Alchemy City West Club House Management Association Other Related party Sale of goods or services 0.58 No Additional Remarks 0.29 0.00 0.00
2 ALEMBIC LIMITED Alchemy City West Club House Management Association Other Related party Any other transaction Reimbursement of Expenses Paid 5.53 No Additional Remarks 5.53 0.00 0.00
3 ALEMBIC LIMITED Alchemy City West Club House Management Association Other Related party Any other transaction Security Deposit Received 0.00 No Additional Remarks 0.00 0.12 0.12 Textual Information(1)
4 ALEMBIC LIMITED ALCHEMY CITY WEST PROJECT MANAGEMENT ASSOCIATION Other Related party Sale of goods or services 0.58 No Additional Remarks 0.28 0.00 0.00
5 ALEMBIC LIMITED ALCHEMY CITY WEST PROJECT MANAGEMENT ASSOCIATION Other Related party Any other transaction Security Deposit Received 0.00 No Additional Remarks 0.00 0.12 0.12 Textual Information(2)
6 ALEMBIC LIMITED Alembic City Limited Subsidiary Any other transaction Commission on Corporate Guarantee 0.64 No Additional Remarks 0.64 0.00 0.00
7 ALEMBIC LIMITED Alembic City Limited Subsidiary Sale of goods or services 8,378.00 No Additional Remarks 2,136.24 0.00 0.00
8 ALEMBIC LIMITED Alembic City Limited Subsidiary Any other transaction Reimbursement of Expenses Paid 236.00 No Additional Remarks 12.89 0.00 0.00
9 ALEMBIC LIMITED Alembic City Limited Subsidiary Any other transaction Reimbursement of Expenses Received 944.00 No Additional Remarks 101.06 0.00 0.00
10 ALEMBIC LIMITED Alembic City Limited Subsidiary Any other transaction Security Deposit Received 187.13 No Additional Remarks 187.13 617.02 804.14
11 ALEMBIC LIMITED Alembic City Limited Subsidiary Investment 0.00 No Additional Remarks 0.00 10.07 10.07 Investment 0 NA Unsecured NA Textual Information(3)
12 ALEMBIC LIMITED Alembic CSR Foundation Other Related party Any other transaction CSR contribution 112.16 No Additional Remarks 56.08 0.00 0.00
13 ALEMBIC LIMITED Alembic Limited Gratuity Fund Other related party Any other transaction Post Employment Benefit Plans 30.00 No Additional Remarks 30.00 0.00 0.00
14 ALEMBIC LIMITED Alembic Limited Provident Fund Other related party Any other transaction Post Employment Benefit Plans 118.16 No Additional Remarks 118.16 0.00 0.00
15 ALEMBIC LIMITED Alembic Pharmaceuticals Limited Associate Sale of goods or services 8,026.00 No Additional Remarks 2,801.84 343.86 437.37
16 ALEMBIC LIMITED Alembic Pharmaceuticals Limited Associate Purchase of goods or services 236.00 No Additional Remarks 16.73 13.63 0.00
17 ALEMBIC LIMITED Alembic Pharmaceuticals Limited Associate Any other transaction Reimbursement of Expenses Received 700.00 No Additional Remarks 150.64 0.00 0.00
18 ALEMBIC LIMITED Alembic Pharmaceuticals Limited Associate Any other transaction Security Deposit Received 67.79 No Additional Remarks 67.79 329.50 397.29
19 ALEMBIC LIMITED Alembic Pharmaceuticals Limited Associate Investment 0.00 No Additional Remarks 0.00 8,665.07 8,665.07 Investment 0 NA Unsecured NA Textual Information(4)
20 ALEMBIC LIMITED Barkha Pranav Amin PROMOTER GROUP Sale of goods or services 271.62 No Additional Remarks 27.16 0.00 0.27
21 ALEMBIC LIMITED Bhailal Amin General Hospital PROMOTER GROUP Sale of goods or services 11.17 No Additional Remarks 5.32 0.00 0.00
22 ALEMBIC LIMITED Bhailal Amin General Hospital PROMOTER GROUP Any other transaction Security Deposit Received 0.00 No Additional Remarks 0.00 2.22 2.22 Textual Information(5)
23 ALEMBIC LIMITED Nirayu Private Limited HOLDING Sale of goods or services 0.58 No Additional Remarks 0.28 0.00 0.00
24 ALEMBIC LIMITED Nirayu Private Limited HOLDING Any other transaction Royalty Charges Paid 15.53 No Additional Remarks 15.53 0.00 0.00
25 ALEMBIC LIMITED Nirayu Private Limited HOLDING Any other transaction Security Deposit Received 0.00 No Additional Remarks 0.00 0.12 0.12 Textual Information(6)
26 ALEMBIC LIMITED Paushak Limited PROMOTER GROUP Sale of goods or services 797.20 No Additional Remarks 46.64 0.00 0.00
27 ALEMBIC LIMITED Paushak Limited PROMOTER GROUP Purchase of goods or services 177.00 No Additional Remarks 0.66 0.00 0.00
28 ALEMBIC LIMITED Paushak Limited PROMOTER GROUP Investment 0.00 No Additional Remarks 0.00 41,602.18 16,251.74 Investment 0 NA Unsecured NA Textual Information(7)
29 ALEMBIC LIMITED Shreno Engineering Limited PROMOTER GROUP Sale of goods or services 0.58 No Additional Remarks 0.28 0.00 0.00
30 ALEMBIC LIMITED Shreno Engineering Limited PROMOTER GROUP Purchase of goods or services 118.00 No Additional Remarks 92.63 0.18 0.00
31 ALEMBIC LIMITED Shreno Engineering Limited PROMOTER GROUP Any other transaction Security Deposit Received 0.00 No Additional Remarks 0.00 0.12 0.12 Textual Information(8)
32 ALEMBIC LIMITED Shreno Limited PROMOTER GROUP Any other transaction Reimbursement of Expenses Received 1,000.00 No Additional Remarks 279.81 51.17 51.05
33 ALEMBIC LIMITED Shreno Publications Limited PROMOTER GROUP Sale of goods or services 109.74 No Additional Remarks 48.32 0.00 0.00
34 ALEMBIC LIMITED Shreno Publications Limited PROMOTER GROUP Purchase of goods or services 118.00 No Additional Remarks 0.11 0.00 0.00
35 ALEMBIC LIMITED Malika Amin PROMOTER Any other transaction Director's Sitting Fees 0.60 No Additional Remarks 0.60 0.00 0.00
36 ALEMBIC LIMITED Malika Amin PROMOTER Remuneration 144.00 No Additional Remarks 36.00 0.00 0.00
37 ALEMBIC LIMITED Chirayu Amin KEY MANAGERIAL PERSONNEL Any other transaction Director's Sitting Fees 1.00 No Additional Remarks 1.00 0.00 0.00
38 ALEMBIC LIMITED Udit Amin PROMOTER Remuneration 1,000.00 No Additional Remarks 375.00 0.00 0.00
39 ALEMBIC CITY LIMITED Alembic Pharmaceuticals Limited Promoter Group Sale of goods or services 50.45 No Additional Remarks 50.45 0.00 0.00 Textual Information(9)
40 ALEMBIC CITY LIMITED Alembic Pharmaceuticals Limited Promoter Group Any other transaction Reimbursement of Expenses Received 6.00 No Additional Remarks 6.00 0.00 0.00 Textual Information(10)
41 ALEMBIC CITY LIMITED Alembic Pharmaceuticals Limited Promoter Group Any other transaction Security Deposit Received 29.44 No Additional Remarks 29.44 3.00 32.44
42 ALEMBIC CITY LIMITED Paushak Limited Promoter Group Sale of goods or services 9.75 No Additional Remarks 9.75 0.00 0.00 Textual Information(11)
43 ALEMBIC CITY LIMITED Paushak Limited Promoter Group Any other transaction Reimbursement of Expenses Received 3.11 No Additional Remarks 3.11 0.00 0.00 Textual Information(12)
44 ALEMBIC CITY LIMITED Paushak Limited Promoter Group Any other transaction Security Deposit Received 0.00 No Additional Remarks 0.00 4.13 4.13 Textual Information(13)
45 ALEMBIC CITY LIMITED Paushak Limited Promoter Group Investment 0.00 No Additional Remarks 0.00 0.71 0.28 Textual Information(14)
46 ALEMBIC CITY LIMITED Shreno Engineering Limited Promoter Group Sale of goods or services 10.33 No Additional Remarks 10.33 0.00 0.00
47 ALEMBIC CITY LIMITED Shreno Engineering Limited Promoter Group Any other transaction Reimbursement of Expenses Received 0.87 No Additional Remarks 0.87 0.00 0.00
48 ALEMBIC CITY LIMITED Shreno Engineering Limited Promoter Group Any other transaction Security Deposit Received 0.00 No Additional Remarks 0.00 4.38 4.38 Textual Information(15)
49 ALEMBIC CITY LIMITED Nirayu Private Limited Promoter Group Any other transaction license fees to use marketing rights 6.08 No Additional Remarks 6.08 0.00 0.00
50 ALEMBIC CITY LIMITED Nirayu Private Limited Promoter Group Any other transaction Royalty Charges Paid 59.00 No Additional Remarks 59.00 0.00 0.00
51 ALEMBIC CITY LIMITED Alembic Pharmaceuticals Limited Promoter Group Investment 0.00 No Additional Remarks 0.00 0.90 0.66 Investment 0 NA Unsecured NA Textual Information(16)
Total value of transaction during the reporting period 6,789.67



Text Block

Textual Information(1) There were no transactions during the period.
Textual Information(2) There were no transactions during the period.
Textual Information(3) There were no transactions during the period.
Textual Information(4) There were no transactions during the period.
Textual Information(5) There were no transactions during the period.
Textual Information(6) There were no transactions during the period.
Textual Information(7) 1.There are no transactions during the period. 2.Change in opening and closing values reflects variation in market price (net of necessary tax adjustments) of shares of the listed entity.
Textual Information(8) There were no transactions during the period.
Textual Information(9) The transaction does not require approval of Audit committee of the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
Textual Information(10) The transaction does not require approval of Audit committee of the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
Textual Information(11) The transaction does not require approval of Audit committee of the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
Textual Information(12) The transaction does not require approval of Audit committee of the listed entiry since the same is not exceeding the threshold of 10 % of the standalone turnover of the subsidairy company.
Textual Information(13) There were no transactions during the period.
Textual Information(14) 1. There were no transaction during the oeriod 2. Changes in the Opening and Closing value reflects variation in Market Price (Net of necessary Tax Adjustments) of shares of the listed entity.
Textual Information(15) There were no transactions during the period.
Textual Information(16) There were no transactions during the period.